4Dx FY16 Update: Share Price Increase to $312.50, Series A Wholesale Capital Raise, Signed Commercial Collaboration Agreements with Three Major US Hospitals

4Dx Ltd is an early stage medical technology company based in Melbourne, Australia, established to commercialise four-dimensional lung imaging technology: 4DxV. The Company had a hugely successful FY15/16 with Share price increasing to $312.50 (from $270 and $100 over the two past years). Major highlights include:

• Establishment of Clinical Advisory Board (CAB) and appointment of two new board members;
• Signed commercial collaboration agreements with three major US hospitals;
• Opened a Series A wholesale capital raise of AU$4M together with a retail fundraising round;
• Established a U.S. office with partial relocation of the management team to Santa Monica, Los Angeles; and
• Increased infrastructure and personnel dedicated to R&D effort in new St Kilda Road office.

ABOUT 4DX

4Dx brings a technological solution set to disrupt this multi-billion dollar sector through compelling unique competitive advantages over existing respiratory diagnostics. The respiratory diagnostic sector represents a global market of over $25B perannum. Currently served by out of date technology, 4Dx has enormous scope for financial success as well as life changing advancement for medicine.

Offering more detailed information, faster validation of treatment efficacy, lower costs, and reduced radiation dosage, 4Dx allows for earlier detection of disease and earlier intervention.The ability to identify lung issues earlier is creating a critical shift in the practice model from cure to prevention.